Clinical Trial: NCT06715826
Target-specific immunoPET Imaging of Breast Cancer
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | RenJi Hospital |
| Information Provided By: | RenJi Hospital |
| Last Update Posted: | 2026-01-27 |
Study Overview
Brief Summary
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Official Title
Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Intervention / Treatment
- Drug: [18F]F-RESCA-RT4
- Drug: [18F]F-RESCA-RB14
Other Study ID Numbers
- KY2024-095-A
Start Date (Actual)
2024-09-21
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2026-11
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | RenJi Hospital |
| Information Provided By: | RenJi Hospital |
| Last Update Posted: | 2026-01-27 |
Study Overview
Brief Summary
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Official Title
Development and Clinical Translation of immunoPET Imaging Probes for Breast Cancer
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Intervention / Treatment
- Drug: [18F]F-RESCA-RT4
- Drug: [18F]F-RESCA-RB14
Other Study ID Numbers
- KY2024-095-A
Start Date (Actual)
2024-09-21
Primary Completion Date (Estimated)
2026-11
Study Completion Date (Estimated)
2026-11
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 1, Phase 2